Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilazapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilazapril SCHEMBL24962 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL16290008 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL29394939 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10368731 | 1.00 | ACE (0.76) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL10562310 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL19469323 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL15263655 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL136488 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL24961 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 | |
| Cilazapril SCHEMBL6508385 | 0.99 | ACE (0.75) | ACELMNAMMEABCB11AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080008751-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008751-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | TEVA PHARMACEUTICALS USA, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008751-A1 | Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof | ACE, CMA1, ACE2 | ACE 1/4885LMNA 2980/4885MME 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.